![Masoud Tavazoie](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ursprung des Netzwerks ersten Grades von Masoud Tavazoie
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Inspirna, Inc.
![]() Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY.
10
| Holding Company | Pharmaceuticals: Major | 10 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Masoud Tavazoie
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | President | |
PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
W WORL | Pharmaceuticals: Major | Corporate Officer/Principal | |
Otsuka Pharmaceutical Co., Ltd.
![]() Otsuka Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Otsuka Pharmaceutical Co. Ltd. engages in the manufacturing, distributing, exporting, and importing of pharmaceuticals, clinical testing equipment, medical device and equipment, food products, cosmetics, and other related products. Its operations are carried out through the following business divisions: Pharmaceutical Business and Nutraceutical Business. The Pharmaceutical Business division engages in the manufacture and sale of pharmaceutical products for the diagnosis and treatment of diseases. The Nutraceutical Business division provides nutritional products, cosmetics and medicines that support day-to-day health maintenance and improvement. The company was founded on August 10, 1964 and is headquartered in Tokyo, Japan. | Pharmaceuticals: Major | Corporate Officer/Principal | |
BAYER AG | Pharmaceuticals: Major | Director/Board Member | |
Bayer Pharmaceuticals Corp. | President | ||
Otsuka Pharmaceutical Development & Commercialization, Inc.
![]() Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Part of Otsuka Holdings Co., Ltd., Otsuka Pharmaceutical Development & Commercialization, Inc. is a healthcare company that was founded in 2007. The company is based in Princeton, NJ. The company is driven by their purpose and defined by their beliefs. | Pharmaceuticals: Major | Corporate Officer/Principal | |
HealthPrize Technologies LLC
![]() HealthPrize Technologies LLC Packaged SoftwareTechnology Services HealthPrize Technologies LLC provides medication adherence solutions for patients. It offers digital platform that improves medication adherence via combination of education and rewards. The company was founded by Thomas Kottler, Katrina Firlik and James Jorasch in September 2009 and is headquartered in Norwalk, CT. | Packaged Software | Director/Board Member | |
Harvard University
![]() Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Graduate Degree Corporate Officer/Principal | |
Stanford University | College/University | Graduate Degree Doctorate Degree | |
The University of Liverpool
![]() The University of Liverpool Other Consumer ServicesConsumer Services The University of Liverpool operates as a university. It offers post graduate research, foundation courses, continuing and professional development, online study, and doctoral college. The company was founded in 1881 and is headquartered in Liverpool, the United Kingdom. | College/University | Doctorate Degree | |
Concordia College (New York) | College/University | Undergraduate Degree | |
Long Island University | College/University | Graduate Degree | |
New York University | College/University | Undergraduate Degree | |
University of California, Santa Barbara | College/University | Undergraduate Degree | |
University of Kansas | College/University | Doctorate Degree | |
Ethicon, Inc.
![]() Ethicon, Inc. Medical SpecialtiesHealth Technology Ethicon, Inc. develops and markets medical products and devices for surgery. It offers different types of services such as wound management, women's health, and cardiovascular surgery. The company was founded by George F. Merson in 1915 and is headquartered in Somerville, NJ. | Medical Specialties | Corporate Officer/Principal | |
Novartis Pharmaceuticals Corp.
![]() Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
University of Leicester | College/University | Corporate Officer/Principal | |
NanoDimension Management Ltd.
![]() NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management (NanoDimension) Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | Investment Managers | Private Equity Investor | |
Bayer Pharma AG
![]() Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Chief Executive Officer | |
Lederle International | Corporate Officer/Principal | ||
Novo Ventures 1 A/S
![]() Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor | |
Ethicon Corp.
![]() Ethicon Corp. Medical SpecialtiesHealth Technology Ethicon Corp. manufactures and markets surgical sutures. The company is headquartered in Somerville, NJ. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
Alliance for Regenerative Medicine
![]() Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Medical/Nursing Services | Director/Board Member | |
CG ONCOLOGY, INC. | Biotechnology | Founder | |
Novo Ventures (US), Inc.
![]() Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | Investment Managers | Private Equity Analyst | |
Amphivena Therapeutics, Inc.
![]() Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Drugstore Chains | Chairman Director/Board Member | |
The Wharton School of the University of Pennsylvania | College/University | Undergraduate Degree | |
Blade Therapeutics, Inc.
![]() Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
REPLIMUNE GROUP, INC. | Biotechnology | Director/Board Member | |
Tmunity Therapeutics, Inc.
![]() Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Miscellaneous Commercial Services | Chief Executive Officer | |
ARCELLX, INC. | Biotechnology | Director/Board Member | |
Confo Therapeutics NV
![]() Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Pharmaceuticals: Major | Chairman | |
Fore Biotherapeutics, Inc.
![]() Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Chairman | |
Comet Therapeutics, Inc.
![]() Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Vesigen, Inc.
![]() Vesigen, Inc. BiotechnologyHealth Technology Vesigen, Inc. develops groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. The company is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Umoja Biopharma, Inc.
![]() Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Chairman | |
COYA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Essenlix Corp.
![]() Essenlix Corp. Medical SpecialtiesHealth Technology Essenlix Corp. develops an instant mobile health self-test platform. The private company is based in Monmouth Junction, NJ. The company was founded in 2013 by Lin Chou and Stephen Y. Chou. | Medical Specialties | Chairman | |
U1 Bio, Inc.
![]() U1 Bio, Inc. Miscellaneous Commercial ServicesCommercial Services U1 Bio, Inc. provides biotechnology research and development services. The CEO of the American company is David Nelles. | Miscellaneous Commercial Services | Director/Board Member | |
LEPU BIOPHARMA CO., LTD. | Pharmaceuticals: Major | Director/Board Member | |
Mnemo Therapeutics SAS
![]() Mnemo Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Mnemo Therapeutics SAS is a French biotechnology company that develops cell therapies to create accessible cures for cancer patients. The company is based in Paris, FR, and has subsidiaries in the United States. The company applies a novel approach to cell therapy using its enfinit platform, a groundbreaking drug discovery engine. Mnemo is committed to addressing the challenges in the field of immuno-oncology, such as a lack of cancer-specific targets, long-term persistence, and sensitivity. The company aims to engineer the future of immunotherapies to transform the lives of people with cancer by discovering novel cancer-specific targets and boosting immune activity to treat solid tumors. The company was founded in 2019 by Alain Maïore and Michel Sadelain. Robert LaCaze has been the CEO of the company since 2022. | Miscellaneous Commercial Services | Chairman | |
Ray Therapeutics, Inc.
![]() Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
Empyrean Neuroscience, Inc.
![]() Empyrean Neuroscience, Inc. Pharmaceuticals: OtherHealth Technology Empyrean Neuroscience is an American genetic engineering company that specializes in developing neuroactive therapeutics to treat neuropsychiatric and neurologic disorders. The company is based in and, but their location is not specified. The company's platform allows for the creation of small molecule therapeutics through precision genetic modification, transformation, and regeneration of fungi and plants. Additionally, their platform enables the discovery of novel small molecules that may exhibit therapeutic properties. | Pharmaceuticals: Other | Chief Executive Officer | |
Reunion Neuroscience, Inc.
![]() Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | Biotechnology | Director/Board Member | |
True North Therapeutics, Inc.
![]() True North Therapeutics, Inc. BiotechnologyHealth Technology True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA. | Biotechnology | Founder Chief Executive Officer |
Statistik
International
Vereinigte Staaten | 39 |
Deutschland | 3 |
Vereinigtes Königreich | 3 |
Frankreich | 3 |
Japan | 2 |
Sektoral
Health Technology | 28 |
Consumer Services | 11 |
Commercial Services | 6 |
Finance | 4 |
Technology Services | 2 |
Operativ
Director/Board Member | 48 |
Corporate Officer/Principal | 28 |
Chairman | 20 |
Independent Dir/Board Member | 11 |
Chief Executive Officer | 11 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Eric Rowinsky | 36 |
Dieter Weinand | 32 |
Peter van Vlasselaer | 15 |
Shahram Seyedin-Noor | 12 |
Usman Azam | 10 |
Raymond Camahort | 8 |
peter vlasselaer | 8 |
Jue Pu | 5 |
Saeed Tavazoie | 1 |
Sohail Tavazoie | 1 |
- Börse
- Insiders
- Masoud Tavazoie
- Unternehmensverbindungen